Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | TXN | P10599 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | APP | P05067 | 1/20 | 0.67 |
| ▸ | KCNH3 | Q9ULD8 | 10/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535866 | 0.93 | TXN (0.82) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL1658574 | 0.89 | TXN (0.89) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL21645541 | 0.89 | TXN (0.89) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL1923883 | 0.89 | MAPT (1.00) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL3499751 | 0.85 | MAPT (0.85) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL23643402 | 0.85 | NFKB1 (0.92) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL8524478 | 0.85 | MEN1 (0.71) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL21655135 | 0.85 | NFKB1 (1.00) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL113103 | 0.85 | NFKB1 (1.00) | MEN1MAPTMAPK1KMT2ANFKB1 | |
| SCHEMBL1924287 | 0.84 | APP (0.70) | MEN1MAPTMAPK1KMT2ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479397-B1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060194803-A1 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1479397-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194803-A1 | 2,4,6-Triamino-1,3,5-triazine derivative | KCNT1, KCNMA1, KCNJ2 | MEN1 2356/4885MAPT 158/4885MAPK1 489/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | MEN1 2356/4885MAPT 158/4885MAPK1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.